20-F: Virax Biolabs Reports Continued Significant Losses Amidst Core Product Development and Capital Raises

Virax Biolabs Group Limited, a biotechnology company focused on T cell in-vitro diagnostics, reported a net loss of $6.07 million for the fiscal year ended March 31, 2025, continuing a trend of substantial operating losses as it invests heavily in its ViraxImmune platform while existing product revenues remain minimal.

Summary

• Virax Biolabs Group Limited, a Cayman Islands holding company, operates through subsidiaries in the UK, US, and China, focusing on T cell In Vitro Diagnostics (IVD) for viral diseases and post-viral syndromes.
• The company reported a net loss of $6,067,232 for the fiscal year ended March 31, 2025, compared to $6,739,120 in 2024 and $5,457,763 in 2023.
• Revenues for the fiscal year 2025 were $6,331, a significant decrease from $156,419 in 2024, primarily from sales of third-party test kits under the ViraxClear and ViraxVet brands, which are not the company's main focus.
• Cost of revenues for 2025 was $59,398, including a $46,904 write-off for expired inventory.
• Operating expenses decreased by approximately 7% to $6,109,830 in 2025 from $6,547,063 in 2024.
• Research and Development (R&D) expenses increased to $1,779,802 in 2025 from $1,561,965 in 2024, driven by increased payroll and materials for the ViraxImmune platform.
• General and administrative costs decreased to $4,330,028 in 2025 from $4,594,743 in 2024, mainly due to lower stock-based compensation.
• The company had an accumulated deficit of $24,589,244 as of March 31, 2025.
• Cash balance as of March 31, 2025, was $4,228,944, an increase from $3,589,244 in 2024, primarily due to financing activities.
• Net cash used in operating activities was $4,563,576 in 2025, a decrease from $6,247,016 in 2024.
• The company completed several capital raises, including an At-the-Market (ATM) offering for $754,511 net proceeds and a registered direct offering for $4,373,675 net proceeds in 2024.
• A 1-for-10 share consolidation was effective December 18, 2023, to regain Nasdaq compliance, which was achieved on January 4, 2024.
• The company received a research and development tax credit of $136,661 in 2025.
• Management concluded that disclosure controls and procedures were not effective as of March 31, 2025, due to a control deficiency in internal control over financial reporting, stating the company is 'too small to effectively assess.'
• Jason Davis, the Chief Financial Officer, resigned effective June 13, 2025.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including recurring substantial losses, minimal and declining revenue from existing products, and a 'going concern' warning. While it is actively developing a promising new platform (ViraxImmune) and has successfully raised capital, the early stage of its core product, lack of patents, and internal control deficiencies present high risks for investors.

Positives

• Increased investment in Research and Development (R&D) for the ViraxImmune platform, with R&D expenses rising to $1,779,802 in 2025.
• Successful capital raises through warrant exercises, an At-the-Market offering, and a registered direct offering, providing $5,807,166 in financing activities for 2025.
• Regained compliance with Nasdaq listing requirements (Rule 5550(a)(2)) following a 1-for-10 share consolidation.
• Received a research and development tax credit of $136,661 in 2025, indicating government support for R&D efforts.
• The company is developing a 'cutting-edge technology' in the ViraxImmune platform, which is intended to be lab-agnostic and easy to use, potentially allowing for broader distribution and rapid market capture.
• Possesses an experienced management team with extensive industry expertise and a global vision, including CEO James Foster and COO Dr. Nigel McCracken.

Negatives

• Continued significant operating losses, with a net loss of $6,067,232 in 2025, and an accumulated deficit of $24,589,244 as of March 31, 2025.
• Revenues are minimal and declining, with only $6,331 in 2025, indicating a lack of significant commercialization for existing products.
• The company has a 'limited operating history' and expects to incur significant losses for the foreseeable future, raising 'substantial doubt' about its ability to continue as a going concern.
• Impairment charge of $390,355 in 2024 for the ViraxImmune Mobile Application, indicating a suspended development and no return on that investment.
• Management concluded that disclosure controls and procedures were not effective as of March 31, 2025, due to a control deficiency in internal control over financial reporting.
• The company currently owns no patents, relying on less robust intellectual property protections like trade secrets, which may limit its ability to prevent copying and increase competition.
• The London lab space lease expired in June 2024 and was not renewed, potentially impacting operational footprint.

Risks

• Limited operating history and expectation of significant losses for the foreseeable future, with no guarantee of achieving or sustaining profitability.
• Significant investments in research and development of new products and services (ViraxImmune) may not be successful or achieve desired results.
• Inability to successfully leverage the ViraxImmune platform to discover, develop, and commercialize additional products and services.
• Uncertainty in obtaining regulatory approvals (e.g., FDA, CE Marking) for ViraxImmune products, which could delay or prevent commercialization.
• Significant challenges in successfully commercializing products in new markets, including establishing sales and marketing capabilities.
• Dependence on market acceptance and increased demand for products by Contract Research Organizations, hospitals, governments, public health departments, physicians, and consumers.
• The success of proprietary T cell testing depends on successful clinical and validation studies, which are expensive, time-consuming, and uncertain.
• New market opportunities may not develop as quickly as expected, limiting the ability to market and sell products successfully.
• Potential liability for improper collection, use, or appropriation of personal information, subject to evolving and strict data protection regulations (e.g., GDPR, PDPA, PRC laws).
• The in-vitro diagnostics industry is subject to rapid change, which could make the company's diagnostics platform and related products obsolete.
• Loss of key members of senior management, key advisors, or other personnel could disrupt operations or strategic plans.
• Dependence on information technology systems, with risks of failures, downtime, or cybersecurity breaches leading to service disruptions, errors, or unauthorized disclosure of confidential information.
• Exposure to unanticipated changes in tax laws and regulations, adjustments to tax provisions, or forfeiture of tax assets.
• Reliance on dividends and other distributions from subsidiaries, with potential limitations on their ability to make payments.
• Share price volatility due to various factors, including operating results, market conditions, and regulatory developments.
• Risk of delisting from Nasdaq if applicable listing requirements are not met.
• No intention to pay cash dividends in the foreseeable future.
• As an emerging growth company and foreign private issuer, the company takes advantage of reduced reporting requirements, which may afford less protection to shareholders.
• Nasdaq may apply additional and more stringent criteria for continued listing due to insiders holding a large portion of listed securities.
• Failure to comply with anti-corruption and anti-money laundering laws (e.g., UK Bribery Act, FCPA) could result in penalties.
• Uncertainties over the interpretation and implementation of the Cayman Islands' economic substance legislation (ES Act) may impact operations.
• Difficulties for U.S. investors in protecting their interests or enforcing judgments due to the company's Cayman Islands incorporation and the location of executive officers and directors outside the U.S.

Future Outlook

The company expects to continue incurring losses for the foreseeable future as it conducts ongoing research and development of its ViraxImmune products and seeks product certification approvals. It anticipates these losses will increase substantially as it hires additional personnel, obtains and protects intellectual property, and incurs commercialization costs. The company plans to fund its cash flow needs through its current cash balance and future debt and/or equity financings, as it does not expect to generate sufficient internal cash flows in the foreseeable future.

Management Comments

• "We are in the process of developing and manufacturing tests that can predict adaptive immunity to viral diseases as well as identify individuals suffering from T cell exhaustion and chronic inflammation linked to post viral syndromes."
• "We believe that the T cell Tests and immunology platform we are developing under the ViraxImmune brand will be particularly useful in assisting in the threat analysis of the major viruses faced globally as well as helping with the early diagnosis of indications associated with T cell exhaustion and chronic inflammation which have been linked to symptoms such as chronic fatigue."
• "We are preparing a Q-submission under the U.S. Food and Drug Administration (FDA) pre-submission program for potential IVD classification of our ViraxImmune assay and anticipate holding the Q-submission meeting during the third quarter of 2025."
• "Our strategic focus is the development and commercialization of immune profiling IVDs in indications associated with chronic inflammation and T cell exhaustion, such as post viral syndromes and other infectious diseases, chronic inflammation and immune-oncology."
• "The Company has determined that it is too small to effectively assess our internal control over financial reporting as of March 31, 2025."

Industry Context

Virax Biolabs operates in the rapidly evolving in-vitro diagnostics (IVD) market, characterized by technological and scientific breakthroughs. The company's strategic focus on T cell diagnostics for chronic inflammation and T cell exhaustion aligns with a perceived increasing incidence of chronic infections and inflammatory disorders. This niche, particularly post-viral syndromes like Long COVID, represents a significant public health challenge with a need for improved diagnostic tools beyond acute infection detection. The industry faces challenges such as regulatory complexities, the need for substantial R&D investment, and intense competition from established players like Qiagen, Adaptive Biotechnologies, Roche, and Abbott, who possess greater resources and market presence. Virax Biolabs aims to differentiate itself through its 'cutting-edge' lab-agnostic ViraxImmune technology.

Comparison to Industry Standards

• Compared to established IVD competitors like Qiagen N.V., Adaptive Biotechnologies Corporation, Roche Holding AG, and Abbott Laboratories, Virax Biolabs has a significantly smaller revenue base ($6,331 vs. multi-billion dollar revenues of competitors) and is in a much earlier stage of product commercialization.
• While competitors have broad and established product offerings, Virax Biolabs is focusing on a specialized, 'cutting-edge' T cell IVD platform (ViraxImmune) for chronic inflammation and T cell exhaustion, which it believes is not currently available on the market.
• The company's R&D expenditure of $1.78 million in 2025 is substantial relative to its minimal revenue, reflecting its development-stage nature, whereas larger competitors have much larger R&D budgets supporting diverse pipelines.
• Unlike many established IVD companies that have extensive patent portfolios, Virax Biolabs currently owns no patents, which is a significant competitive disadvantage in a technology-driven industry.
• The company's strategy to develop a 'lab agnostic' and 'easy to use' T cell IVD aims to overcome the lab-specific nature of many existing IVD kits, potentially allowing for broader geographic reach and rapid deployment compared to conventional technologies marketed by competitors.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not involved in any legal or arbitration proceedings that may have or have had in the recent past, significant effects on its financial position or profitability.

Related Party Transactions

• As of March 31, 2025, related party payables consisted of accrued bonuses totaling $337,576, including $119,700 for James Foster, $110,100 for Jason Davis, and $107,776 for Nigel McCracken.

Stakeholder Impact

• **Shareholders**: Face significant risk due to recurring losses, accumulated deficit, and a 'going concern' warning. Share price volatility is expected. Dilution risk from ongoing capital raises. Less protection due to foreign private issuer status.
• **Employees**: The company's continued losses and dependence on future financing could impact job security. However, the company is investing in R&D and expanding its team, particularly in R&D (13 personnel, 68% of total employees).
• **Customers (Contract Research Organizations, hospitals, governments, public health departments, physicians, consumers)**: Future success depends on market acceptance of new ViraxImmune products. Current revenue from existing products is minimal and declining, indicating limited current customer impact from those lines.
• **Suppliers**: The company works closely with suppliers to assure continuity of supply, but its financial instability could pose a risk to supplier relationships if not managed effectively.
• **Creditors**: The 'going concern' warning and accumulated deficit indicate increased risk for creditors, though the company has recently raised significant capital.

Next Steps

• Continue research and development of the ViraxImmune suite of IVD T cell test kits, focusing on post-viral syndromes and chronic inflammation.
• Prepare and hold a Q-submission meeting with the U.S. Food and Drug Administration (FDA) during the third quarter of 2025 for potential IVD classification of the ViraxImmune assay.
• Apply for CE Marking with the European Union for medical device products, followed by application for a UK Conformity Assessed mark with the UK Medicine and Healthcare Products Regulatory Agency.
• Launch expanded sales and marketing efforts, including further collaboration with international industry leaders and governments, and penetrating mature regions like the United Kingdom, European Union, and North America.
• Recruit employees to expand the sales team in targeted regions (United States, Canada, European Union).
• Work alongside appropriate governmental healthcare providers to incorporate the ViraxImmune test into healthcare systems and pharmacy outlets.
• Generate longitudinal samples in Long COVID, RSV, and influenza patients through collaboration on the UK ImRESP trial for the development and technical performance of IVD diagnostics.
• Actively evaluate patent filings to protect ongoing innovations related to proprietary immune profiling technologies.
• Management will continue to monitor and evaluate the effectiveness of internal controls and procedures over financial reporting and implement additional improvements as necessary.

Key Dates

Recommendation

Keywords

Biotechnology, In Vitro Diagnostics, IVD, T cell diagnostics, Immune profiling, ViraxImmune, Post-viral syndromes, Chronic inflammation, T cell exhaustion, SARS-CoV-2, HPV, Malaria, Hepatitis B, Herpes, Long COVID, CAR-T therapies, Myloid Encephalomyelitis, Medical devices, Regulatory approval, FDA, CE Marking, Nasdaq, SEC filing, Financial results, Net loss, Research and development, Capital raise, Going concern, Intellectual property, Corporate governance, Risk management